Related references
Note: Only part of the references are listed.High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2015)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
HER2/neu testing in primary colorectal carcinoma
B. Ingold Heppner et al.
BRITISH JOURNAL OF CANCER (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
An Na Seo et al.
PLOS ONE (2014)
Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
Carlos Gomez-Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer
Erik J. Blok et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2013)
Quantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis
Jennifer Jeung et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
Marta Herreros-Villanueva et al.
MOLECULAR BIOLOGY REPORTS (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
S. Guiu et al.
BRITISH JOURNAL OF CANCER (2010)
Expression of HER2 in colorectal cancer does not correlate with prognosis
Wieslaw Janusz Kruszewski et al.
DISEASE MARKERS (2010)
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
Andreas H. Marx et al.
HUMAN PATHOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
Josef Rueschoff et al.
VIRCHOWS ARCHIV (2010)
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Dara O. Kavanagh et al.
BMC CANCER (2009)
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
Giuseppe Gullo et al.
INVESTIGATIONAL NEW DRUGS (2009)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
Allen M. Gown et al.
MODERN PATHOLOGY (2008)
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma
Kitty Pavlakis et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2007)
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer
Dong Il Park et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers:: an immunohistochemical and fluorescent in situ hybridization study
A Ooi et al.
MODERN PATHOLOGY (2004)
Low overexpression of HER-2/PPPNeu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin (R)) and irinotecan as therapy. A phase II trial
RK Ramanathan et al.
CANCER INVESTIGATION (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The HER-2/neu oncogene in tumors of the gastrointestinal tract
JS Ross et al.
CANCER INVESTIGATION (2001)
Share Paper
